A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

This study has suspended participant recruitment.
(Study suspended prior to enrollment)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company )
ClinicalTrials.gov Identifier:
NCT01604863
First received: January 23, 2012
Last updated: October 29, 2012
Last verified: October 2012

January 23, 2012
October 29, 2012
June 2012
June 2014   (final data collection date for primary outcome measure)
  • Maximum Tolerated Dose (MTD) [ Time Frame: Up to 1 year or longer if indicated. ] [ Designated as safety issue: Yes ]
  • Number of participants with adverse events [ Time Frame: Up to 1 year or longer if indicated. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01604863 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies

The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.

This study will consist of 3 regimens each containing 2 dose levels of HGS1036 and full dose chemotherapy. Patients will be treated in sequence with HGS1036 at planned dose levels of 10 mg/kg and 20 mg/kg. Patients who demonstrate stable disease or better may continue to receive HGS1036 until progressive disease, unacceptable toxicity, patient requests discontinuation of study treatment, or the Investigator feels further treatment is not in the patient's best interest. After discontinuation of HGS1036, subjects will be followed for 30 days after the last dose of HGS1036 for safety. The end of study will be defined as 1 year after the last subject begins treatment of HGS1036. Any subject still receiving HGS1036 at this pre-defined end of study, may continue to receive HGS1036, but the only study assessments required will be for safety.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cancer
  • Drug: HGS1036 + Paclitaxel + Carboplatin
    HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
  • Drug: HGS1036 + Cisplatin + Etoposide
    HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
  • Drug: HGS1036 + Docetaxel
    HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
  • Experimental: Arm A
    HGS1036 + Paclitaxel + Carboplatin
    Intervention: Drug: HGS1036 + Paclitaxel + Carboplatin
  • Experimental: Arm B
    HGS1036 + Cisplatin + Etoposide
    Intervention: Drug: HGS1036 + Cisplatin + Etoposide
  • Experimental: Arm C
    HGS1036 + Docetaxel
    Intervention: Drug: HGS1036 + Docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
54
July 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a histological or cytological diagnosis of malignant solid neoplasm requiring systemic chemotherapy.
  • Age ≥18 years.
  • ECOG performance status 0-1.
  • Adequate organ function.
  • Adequate hematological function.
  • Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.
  • Consent to collection of previously obtained, archival biopsy or surgical specimens of the currently treated malignancy when available.

Exclusion Criteria:

  • Significant cardiac disease.
  • Eye trauma or disease.
  • Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months prior to first dose of HGS1036.
  • Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of HGS1036.
  • Major surgery within 4 weeks of the first dose of HGS1036.
  • Prior organ or allogeneic stem cell transplant.
  • Non-healing or chronic wounds.
  • Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.
  • Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of the first dose of HGS1036.
  • Active CNS involvement by primary or metastatic tumor.
  • Documented active infection requiring the use of systemic antibiotics.
  • Pregnancy or lactation.
  • Known HIV-positive serology, AIDS, or an AIDS-related illness.
  • Conditions likely to increase the potential for abdominal perforation or fistula formation.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01604863
HGS1036-C1118
No
GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company )
Human Genome Sciences Inc., a GSK Company
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP